Trial Profile
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients With Secondary Hyperoxaluria and Kidney Stones
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2019
Price :
$35
*
At a glance
- Drugs Reloxaliase (Primary)
- Indications Hyperoxaluria; Renal calculi
- Focus Therapeutic Use
- Sponsors Allena Pharmaceuticals
- 17 Oct 2019 According to an Allena Pharmaceuticals media release, pooled results from three phase II studies will be presented at the American Society of Nephrology (ASN) Kidney Week 2019.
- 17 Jan 2017 Status changed from active, no longer recruiting to completed.
- 14 Dec 2016 Planned End Date changed from 1 Jul 2017 to 1 Apr 2017.